On March 3, 2025, Robert Mauch, President & Chief Executive Officer of a branch of Cencora Inc (COR, Financial), executed a sale of 4,970 shares of the company, as reported in a SEC Filing. Following this transaction, the insider now holds 51,070 shares of Cencora Inc. Cencora Inc is a global healthcare solutions company that provides pharmaceutical distribution and related services designed to improve patient outcomes. The company operates in various segments, including pharmaceutical distribution, specialty solutions, and consulting services, catering to healthcare providers, pharmaceutical manufacturers, and patients. Over the past year, Robert Mauch has sold a total of 62,534 shares and has not made any purchases. This activity is part of a broader trend within the company, where there have been 23 insider sells and only 1 insider buy over the same period. On the day of the recent sale, shares of Cencora Inc were trading at $255 each, giving the stock a market cap of $49,063.525 million. The company's price-earnings ratio stands at 36.03, which is higher than the industry median of 18.7 and also above the company's historical median price-earnings ratio. The stock's price of $255 compared to its GF Value of $238.38 results in a price-to-GF-Value ratio of 1.07, indicating that the stock is fairly valued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples, a GuruFocus adjustment factor, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
